Digoxin tablets

Quốc gia: Armenia

Ngôn ngữ: Tiếng Anh

Nguồn: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Thành phần hoạt chất:

digoxin

Sẵn có từ:

Arpimed LLC

Mã ATC:

C01AA05

INN (Tên quốc tế):

digoxin

Liều dùng:

0,25mg

Dạng dược phẩm:

tablets

Các đơn vị trong gói:

(40/1x40/), in blister

Loại thuốc theo toa:

Prescription

Tình trạng ủy quyền:

Registered

Ngày ủy quyền:

2015-09-24

Đặc tính sản phẩm

SUMMARY
PRODUCT
CHARACTERISTIC
(SPC)
DIGOXIN
0,25
MG
TABLETS
l.lNAME
OF
THE
MEDICINAL
PRODUCT
-
Digoxin
1.2
INTERNATIONAL
NON-PROPERTY
NAME
-
Digoxin
2.
Qualitative
and
quantitative
composition
Each
tablet
contains:
active
ingreelient:
digoxin
-
0.25
mg
inaetive
ingredients:
see
6.
1.
List
of
excipients
3.
Pharmaceutical
form
Tablets
White
flat
scored
tablets
4.
Clinical
particulars
4.
I
Therapeutic
indications
Digoxin
is
a
cardiac
glycoside
used
in
the
management
of
supraventricular
arrhythmias,
and
in
heart
failwe.
ln
heart
fuilure
the
increased
force
of
myocardial
contraction
results
in
increased
cardiac
output,
decreased
end-systolic
volume,
decreased
heart
size,
and
decreased
end-diastolic
pressure
and volume.
Increased
blood
flow
through
the
kidneys
results in
diuresis
with
a reduction
in
oedema
and
blood
volume.
The
decrease
in
puhnonary
venous
pressure
relieves
dyspnoea
and orthopnoea.
In atrial
aruhythmias
digoxin's
actions
cause
a
decrease
in
the
conduction
velocity
through
the
AV
node
and
an
increase
in
the
effective
refractory period,
thus
reducing
venhicular
rate.
ln
addition
there
is
a
decrsase
in
the
refractory
period
of
the
cardiac
muscle
and
depression
of
the
sinus
node
partly
in
response
to
the
increase
in
vagal
activity.
ln
atrialJibrillation,
digoxin
can
cause
rapid
ventricular
rates,
and
possibly
ventricular
fibrillation,
and
should
be
avoided.
It
may
be
given
to
reiieve
an
attack
af
paroxismal
supraventricular
tachycurdiu
and
has also
been
given
to
prevent
further
attacks.
4.2
Posology
and
method
of
administration
Digoxin
has a
narrow
therapeutic
index.
Effect
appear
within
about
2
hours
and
the
maximum
effect
may
be reached
in
about
6
hours.
Initially
a
loading
dose
may
be
given
to
digitalise
the
patient,
although this
may
not
be
necessary
in,
for
example,
mild
heart
failure.
Dosage
depends
on
individual
patient.
Factors
which
may be considered
include
the
patient,s
age,
Iean
body-mass,
renal
status,
thyroid
status,
elecholyte
balance,
degree
of
tissue
oxygenation,
and the
nature
of
the
und